October 8, 2013

Part II: Counseling, Safe Use, and Drug Information


The American Academy of Hospice & Palliative Care Medicine has announced a two-part webinar series to educate clinicians on how to reduce the potential for serious adverse outcomes resulting from inappropriate prescribing, misuse, and abuse of Extended Release/Long Acting (ER/LA) opioid analgesics, while ensuring continued access for patients with legitimate need for these drugs.  

There is no cost to participate in this webinar, but registration is required. Registration will open for Part II by September 16, 2013.  Learn more and register today.

Part II: Counseling, Safe Use, and Drug Information
Tuesday, October 8, 2013 3:00 pm ET
1.0   AMA PRA Category 1 Credits™

Primary care providers, hospice and palliative care providers, pain management, addiction and palliative care specialists, and clinicians struggle to successfully manage their patients' pain. For many patients, long-acting and extended-release opioid medications constitute an effective and valuable element in the pain management plan. However, opioid prescriptions involve many complex issues of misuse, abuse, addiction, adverse effects, and fear of legal and regulatory action. In order to address risk and safety concerns, reduce serious adverse outcomes, and simultaneously ensure that pain patients maintain necessary access to opioids, the U. S. Food and Drug Administration (FDA) has developed a Risk Evaluation and Mitigation Strategy (REMS) that applies to all long-acting and extended-release opioid medications.

Ronald J. Crossno, MD, FAAFP FAAHPM
Senior National Hospice Medical Director
Gentiva Health Services

John Manfredonia, DO FACOFP FAAHPM
National Medical Director for the Hospice Division
Gentiva Health Services

| Add to my Outlook® Calendar